Year |
Citation |
Score |
2018 |
Liu H, Saffi GT, Vasefi MS, Choi Y, Kruk JS, Ahmed N, Gondora N, Mielke J, Leonenko Z, Beazely MA. Amyloid-β inhibits PDGFβ receptor activation and prevents PDGF-BB-induced neuroprotection. Current Alzheimer Research. PMID 29332578 DOI: 10.2174/1567205015666180110110321 |
0.41 |
|
2015 |
Kruk JS, Vasefi MS, Gondora N, Ahmed N, Heikkila JJ, Beazely MA. Fluoxetine-induced transactivation of the platelet-derived growth factor type β receptor reveals a novel heterologous desensitization process. Molecular and Cellular Neurosciences. 65: 45-51. PMID 25702926 DOI: 10.1016/J.Mcn.2015.02.013 |
0.462 |
|
2014 |
Samarajeewa A, Goldemann L, Vasefi MS, Ahmed N, Gondora N, Khanderia C, Mielke JG, Beazely MA. 5-HT7 receptor activation promotes an increase in TrkB receptor expression and phosphorylation. Frontiers in Behavioral Neuroscience. 8: 391. PMID 25426041 DOI: 10.3389/Fnbeh.2014.00391 |
0.492 |
|
2014 |
Kruk JS, Kouchmeshky A, Grimberg N, Rezkella M, Beazely MA. Transactivation of receptor tyrosine kinases by dopamine receptors Dopamine Receptor Technologies. 211-227. DOI: 10.1007/978-1-4939-2196-6_12 |
0.405 |
|
2013 |
Kruk JS, Vasefi MS, Heikkila JJ, Beazely MA. Reactive oxygen species are required for 5-HT-induced transactivation of neuronal platelet-derived growth factor and TrkB receptors, but not for ERK1/2 activation. Plos One. 8: e77027. PMID 24086766 DOI: 10.1371/Journal.Pone.0077027 |
0.461 |
|
2013 |
Vasefi MS, Yang K, Li J, Kruk JS, Heikkila JJ, Jackson MF, MacDonald JF, Beazely MA. Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons. Molecular Brain. 6: 24. PMID 23672716 DOI: 10.1186/1756-6606-6-24 |
0.469 |
|
2013 |
Vasefi MS, Kruk JS, Heikkila JJ, Beazely MA. 5-Hydroxytryptamine type 7 receptor neuroprotection against NMDA-induced excitotoxicity is PDGFβ receptor dependent. Journal of Neurochemistry. 125: 26-36. PMID 23336565 DOI: 10.1111/Jnc.12157 |
0.483 |
|
2013 |
Kruk JS, Vasefi MS, Liu H, Heikkila JJ, Beazely MA. 5-HT(1A) receptors transactivate the platelet-derived growth factor receptor type beta in neuronal cells. Cellular Signalling. 25: 133-43. PMID 23006663 DOI: 10.1016/J.Cellsig.2012.09.021 |
0.485 |
|
2012 |
Vasefi MS, Kruk JS, Liu H, Heikkila JJ, Beazely MA. Activation of 5-HT7 receptors increases neuronal platelet-derived growth factor β receptor expression. Neuroscience Letters. 511: 65-9. PMID 22285262 DOI: 10.1016/J.Neulet.2012.01.016 |
0.447 |
|
2010 |
Peng F, Yao H, Bai X, Zhu X, Reiner BC, Beazely M, Funa K, Xiong H, Buch S. Platelet-derived growth factor-mediated induction of the synaptic plasticity gene Arc/Arg3.1. The Journal of Biological Chemistry. 285: 21615-24. PMID 20452974 DOI: 10.1074/Jbc.M110.107003 |
0.442 |
|
2010 |
Bartos JA, Ulrich JD, Li H, Beazely MA, Chen Y, Macdonald JF, Hell JW. Postsynaptic clustering and activation of Pyk2 by PSD-95. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 449-63. PMID 20071509 DOI: 10.1523/Jneurosci.4992-08.2010 |
0.39 |
|
2009 |
Yang K, Trepanier CH, Li H, Beazely MA, Lerner EA, Jackson MF, MacDonald JF. Vasoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission. Hippocampus. 19: 779-89. PMID 19173226 DOI: 10.1002/Hipo.20559 |
0.479 |
|
2009 |
Beazely MA, Lim A, Li H, Trepanier C, Chen X, Sidhu B, Macdonald JF. Platelet-derived growth factor selectively inhibits NR2B-containing N-methyl-D-aspartate receptors in CA1 hippocampal neurons. The Journal of Biological Chemistry. 284: 8054-63. PMID 19106110 DOI: 10.1074/Jbc.M805384200 |
0.441 |
|
2008 |
Beazely MA, Weerapura M, MacDonald JF. Abelson tyrosine kinase links PDGFbeta receptor activation to cytoskeletal regulation of NMDA receptors in CA1 hippocampal neurons. Molecular Brain. 1: 20. PMID 19077273 DOI: 10.1186/1756-6606-1-20 |
0.515 |
|
2008 |
Thompson RJ, Jackson MF, Olah ME, Rungta RL, Hines DJ, Beazely MA, MacDonald JF, MacVicar BA. Activation of pannexin-1 hemichannels augments aberrant bursting in the hippocampus. Science (New York, N.Y.). 322: 1555-9. PMID 19056988 DOI: 10.1126/Science.1165209 |
0.387 |
|
2007 |
MacDonald JF, Jackson MF, Beazely MA. G protein-coupled receptors control NMDARs and metaplasticity in the hippocampus. Biochimica Et Biophysica Acta. 1768: 941-51. PMID 17261268 DOI: 10.1016/J.Bbamem.2006.12.006 |
0.432 |
|
2006 |
MacDonald JF, Jackson MF, Beazely MA. Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors. Critical Reviews in Neurobiology. 18: 71-84. PMID 17725510 DOI: 10.1615/Critrevneurobiol.V18.I1-2.80 |
0.424 |
|
2006 |
Beazely MA, Tong A, Wei WL, Van Tol H, Sidhu B, MacDonald JF. D2-class dopamine receptor inhibition of NMDA currents in prefrontal cortical neurons is platelet-derived growth factor receptor-dependent. Journal of Neurochemistry. 98: 1657-63. PMID 16879713 DOI: 10.1111/J.1471-4159.2006.04064.X |
0.472 |
|
2006 |
Beazely MA, Watts VJ. Regulatory properties of adenylate cyclases type 5 and 6: A progress report. European Journal of Pharmacology. 535: 1-12. PMID 16527269 DOI: 10.1016/J.Ejphar.2006.01.054 |
0.611 |
|
2005 |
Macdonald DS, Weerapura M, Beazely MA, Martin L, Czerwinski W, Roder JC, Orser BA, MacDonald JF. Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 11374-84. PMID 16339032 DOI: 10.1523/Jneurosci.3871-05.2005 |
0.521 |
|
2005 |
Beazely MA, Watts VJ. Galphaq-coupled receptor signaling enhances adenylate cyclase type 6 activation. Biochemical Pharmacology. 70: 113-20. PMID 15885660 DOI: 10.1016/J.Bcp.2005.04.007 |
0.659 |
|
2005 |
Beazely MA, Watts VJ. Activation of a novel PKC isoform synergistically enhances D2L dopamine receptor-mediated sensitization of adenylate cyclase type 6. Cellular Signalling. 17: 647-53. PMID 15683739 DOI: 10.1016/J.Cellsig.2004.10.003 |
0.677 |
|
2005 |
Beazely MA, Alan JK, Watts VJ. Protein kinase C and epidermal growth factor stimulation of Raf1 potentiates adenylyl cyclase type 6 activation in intact cells. Molecular Pharmacology. 67: 250-9. PMID 15470083 DOI: 10.1124/Mol.104.001370 |
0.654 |
|
2004 |
Johnston CA, Beazely MA, Bilodeau ML, Andrisani O, Watts VJ. Differentiation-induced alterations in cyclic AMP signaling in the Cath.a differentiated (CAD) neuronal cell line. Journal of Neurochemistry. 88: 1497-508. PMID 15009651 DOI: 10.1046/J.1471-4159.2004.02285.X |
0.649 |
|
2002 |
Johnston CA, Beazely MA, Vancura AF, Wang JK, Watts VJ. Heterologous sensitization of adenylate cyclase is protein kinase A-dependent in Cath.a differentiated (CAD)-D2L cells. Journal of Neurochemistry. 82: 1087-96. PMID 12358756 DOI: 10.1046/J.1471-4159.2002.01033.X |
0.677 |
|
Low-probability matches (unlikely to be authored by this person) |
2012 |
Mohamed T, Yeung JC, Vasefi MS, Beazely MA, Rao PP. Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template. Bioorganic & Medicinal Chemistry Letters. 22: 4707-12. PMID 22704921 DOI: 10.1016/J.Bmcl.2012.05.077 |
0.271 |
|
2023 |
Robinson MJ, Newbury S, Singh K, Leonenko Z, Beazely MA. The Interplay Between Cholesterol and Amyloid-β on HT22 Cell Viability, Morphology, and Receptor Tyrosine Kinase Signaling. Journal of Alzheimer's Disease : Jad. 96: 1663-1683. PMID 38073391 DOI: 10.3233/JAD-230753 |
0.263 |
|
2016 |
Osman W, Mohamed T, Sit VM, Vasefi MS, Beazely MA, Rao PP. Structure-Activity Relationship Studies of Benzyl, Phenethyl and Pyridyl Substituted Tetrahydroacridin-9-amines as Multi-targeting Agents to treat Alzheimer's Disease. Chemical Biology & Drug Design. PMID 27282589 DOI: 10.1111/Cbdd.12800 |
0.254 |
|
2016 |
Bradley RM, Mardian EB, Marvyn PM, Vasefi MS, Beazely MA, Mielke JG, Duncan RE. Data on acylglycerophosphate acyltransferase 4 (AGPAT4) during murine embryogenesis and in embryo-derived cultured primary neurons and glia. Data in Brief. 6: 28-32. PMID 26759825 DOI: 10.1016/J.Dib.2015.11.033 |
0.251 |
|
2023 |
Khavandi M, Rao PPN, Beazely MA. Differential Effects of Endocannabinoids on Amyloid-Beta Aggregation and Toxicity. International Journal of Molecular Sciences. 24. PMID 36674424 DOI: 10.3390/ijms24020911 |
0.247 |
|
2015 |
Tin G, Mohamed T, Gondora N, Beazely MA, Rao PPN. Tricyclic phenothiazine and phenoselenazine derivatives as potential multi-targeting agents to treat Alzheimer's disease Medchemcomm. 6: 1930-1941. DOI: 10.1039/C5Md00274E |
0.234 |
|
2021 |
Gondora N, Pople CB, Tandon G, Robinson M, Solomon E, Beazely MA, Mielke JG. Chronic early-life social isolation affects NMDA and TrkB receptor expression in a sex-specific manner. Neuroscience Letters. 136016. PMID 34111511 DOI: 10.1016/j.neulet.2021.136016 |
0.228 |
|
2019 |
Lai D, Pham AT, Nekkar Rao PP, Beazely MA. The effects of heat and freeze-thaw cycling on naloxone stability. Harm Reduction Journal. 16: 17. PMID 30813917 DOI: 10.1186/S12954-019-0288-4 |
0.221 |
|
2000 |
Dimmock JR, Kumar P, Nazarali AJ, Motaganahalli NL, Kowalchuk TP, Beazely MA, Wilson Quail J, Oloo EO, Allen TM, Szydlowski J, DeClercq E, Balzarini J. Cytotoxic 2,6-bis(arylidene)cyclohexanones and related compounds. European Journal of Medicinal Chemistry. 35: 967-77. PMID 11137225 DOI: 10.1016/S0223-5234(00)01173-9 |
0.214 |
|
2023 |
Livingstone JD, Gingras MJP, Leonenko Z, Beazely MA. Search for lithium isotope effects in neuronal HT22 cells. Biochemistry and Biophysics Reports. 34: 101461. PMID 37063814 DOI: 10.1016/j.bbrep.2023.101461 |
0.21 |
|
2014 |
Alqawlaq S, Sivak JM, Huzil JT, Ivanova MV, Flanagan JG, Beazely MA, Foldvari M. Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: towards non-invasive glaucoma gene therapy. Nanomedicine : Nanotechnology, Biology, and Medicine. 10: 1637-47. PMID 24905400 DOI: 10.1016/J.Nano.2014.05.010 |
0.209 |
|
2021 |
Gondora N, Sanyal C, Carter C, Nethercott A, Sproule B, Turcotte D, Halpape K, Bishop LD, Nissen L, Beazely MA, Kwong M, Versteeg S, Chang F. The role of pharmacists in opioid stewardship: Protocol. Research in Social & Administrative Pharmacy : Rsap. 17: 993-996. PMID 33773640 DOI: 10.1016/J.Sapharm.2020.06.027 |
0.206 |
|
2020 |
Tsuyuki RT, Arora V, Barnes M, Beazely MA, Boivin M, Christofides A, Patel H, Laroche J, Sihota A, So R. Canadian national consensus guidelines for naloxone prescribing by pharmacists. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 153: 347-351. PMID 33282024 DOI: 10.1177/1715163520949973 |
0.198 |
|
2016 |
Grindrod K, Beazely M. Fitting naloxone into community pharmacy practice. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 149: 329-331. PMID 27829855 DOI: 10.1177/1715163516671968 |
0.173 |
|
2021 |
Robinson M, Lou J, Mehrazma B, Rauk A, Beazely M, Leonenko Z. Pseudopeptide Amyloid Aggregation Inhibitors: In Silico, Single Molecule and Cell Viability Studies. International Journal of Molecular Sciences. 22. PMID 33494369 DOI: 10.3390/ijms22031051 |
0.148 |
|
2024 |
Cid A, Mahajan N, Wong WWL, Beazely M, Grindrod KA. An economic evaluation of community pharmacy-dispensed naloxone in Canada. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 157: 84-94. PMID 38463179 DOI: 10.1177/17151635241228241 |
0.12 |
|
2022 |
Alkabbani W, Pelletier R, Beazely MA, Labib Y, Quan B, Gamble JM. Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. Drug Safety. 45: 287-295. PMID 35247195 DOI: 10.1007/s40264-022-01166-3 |
0.11 |
|
1999 |
Dimmock JR, Elias DW, Beazely MA, Kandepu NM. Bioactivities of chalcones. Current Medicinal Chemistry. 6: 1125-49. PMID 10519918 |
0.108 |
|
2023 |
Deline ML, Straub J, Patel M, Subba P, Grashei M, van Heijster FHA, Pirkwieser P, Somoza V, Livingstone JD, Beazely M, Kendall B, Gingras MJP, Leonenko Z, Höschen C, Harrington G, et al. Lithium isotopes differentially modify mitochondrial amorphous calcium phosphate cluster size distribution and calcium capacity. Frontiers in Physiology. 14: 1200119. PMID 37781224 DOI: 10.3389/fphys.2023.1200119 |
0.085 |
|
2021 |
Daskalakis G, Cid A, Grindrod K, Beazely MA. Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another. Pharmacy (Basel, Switzerland). 9. PMID 34449716 DOI: 10.3390/pharmacy9030129 |
0.07 |
|
2022 |
Cid A, Patten A, Beazely M, Grindrod K, Yessis J, Chang F. Protocol for the Optimizing Naloxone Dispensing in Pharmacies (ONDP) Online Continuing Education Program: A Randomized Controlled Trial. Pharmacy (Basel, Switzerland). 10. PMID 35202073 DOI: 10.3390/pharmacy10010024 |
0.067 |
|
1999 |
Dimmock JR, Semple HA, John S, Beazely MA, Abrams GD. Isolation and identification of the major urinary metabolite of 4-(4-fluorophenoxy)benzaldehyde semicarbazone after oral dosing to rats. Die Pharmazie. 54: 260-2. PMID 10234738 |
0.065 |
|
2021 |
Gondora N, Versteeg SG, Carter C, Bishop LD, Sproule B, Turcotte D, Halpape K, Beazely MA, Dattani S, Kwong M, Nissen L, Chang F. The role of pharmacists in opioid stewardship: A scoping review. Research in Social & Administrative Pharmacy : Rsap. PMID 34261590 DOI: 10.1016/j.sapharm.2021.06.018 |
0.059 |
|
2021 |
Cid A, Daskalakis G, Grindrod K, Beazely MA. What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review. Pharmacy (Basel, Switzerland). 9. PMID 33540676 DOI: 10.3390/pharmacy9010030 |
0.055 |
|
2021 |
Beazely MA, Tsuyuki RT. The opioid crisis: Naloxone and pharmacists to the rescue. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 154: 289-290. PMID 34484476 DOI: 10.1177/17151635211035127 |
0.053 |
|
2022 |
Cid A, Patten A, Grindrod K, Beazely MA. Frequently asked questions about naloxone: Part 3. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 155: 9-11. PMID 35035636 DOI: 10.1177/17151635211056571 |
0.037 |
|
2021 |
Cid A, Patten A, Grindrod K, Beazely MA. Frequently asked questions about naloxone: Part 2. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 154: 385-387. PMID 34777648 DOI: 10.1177/17151635211045966 |
0.037 |
|
2021 |
Cid A, Patten A, Grindrod K, Beazely MA. Frequently asked questions about naloxone: Part 1. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 154: 301-304. PMID 34484479 DOI: 10.1177/17151635211034528 |
0.037 |
|
2020 |
So R, Al Hamarneh Y, Barnes M, Beazely MA, Boivin M, Laroche J, Patel H, Sihota A, Smith T, Tsuyuki RT. The status of naloxone in community pharmacies across Canada. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 153: 352-356. PMID 33282025 DOI: 10.1177/1715163520958435 |
0.034 |
|
2021 |
Parihar V, Beazely MA, Katz L, Dhami R, Patterson LL. Assessing the impact of a cannabis course on pharmacy students' understanding, beliefs and preparedness regarding medical and recreational cannabis. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 155: 50-59. PMID 35035642 DOI: 10.1177/17151635211041041 |
0.025 |
|
Hide low-probability matches. |